OTLK vs. CHRS, CSBR, TARA, BCLI, IDRA, ITOS, VALN, HLVX, EXAI, and TSHA
Should you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Coherus BioSciences (CHRS), Champions Oncology (CSBR), Protara Therapeutics (TARA), Brainstorm Cell Therapeutics (BCLI), Idera Pharmaceuticals (IDRA), iTeos Therapeutics (ITOS), Valneva (VALN), HilleVax (HLVX), Exscientia (EXAI), and Taysha Gene Therapies (TSHA). These companies are all part of the "biological products, except diagnostic" industry.
Outlook Therapeutics (NASDAQ:OTLK) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Coherus BioSciences received 282 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. However, 70.45% of users gave Outlook Therapeutics an outperform vote while only 65.13% of users gave Coherus BioSciences an outperform vote.
In the previous week, Outlook Therapeutics had 1 more articles in the media than Coherus BioSciences. MarketBeat recorded 5 mentions for Outlook Therapeutics and 4 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.73 beat Outlook Therapeutics' score of 0.40 indicating that Coherus BioSciences is being referred to more favorably in the news media.
Outlook Therapeutics has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Outlook Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
Outlook Therapeutics currently has a consensus target price of $46.43, suggesting a potential upside of 556.65%. Coherus BioSciences has a consensus target price of $8.83, suggesting a potential upside of 385.35%. Given Outlook Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than Coherus BioSciences.
Outlook Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -19.64%. Coherus BioSciences' return on equity of 0.00% beat Outlook Therapeutics' return on equity.
11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 5.3% of Outlook Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Coherus BioSciences beats Outlook Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Outlook Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outlook Therapeutics Competitors List
Related Companies and Tools
